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Polyglutamine expansion within the androgen receptor (AR)
causes spinal and bulbar muscular atrophy (SBMA) and is asso-
ciated with misfolded and aggregated species of the mutant AR.
We showed previously that nuclear localization of the mutant
AR was necessary but not sufficient for SBMA. Here we show
that an interdomain interaction of the AR that is central to its
function within the nucleus is required for AR aggregation and
toxicity. Ligands that prevent the interaction between the
amino-terminal FXXLF motif and carboxyl-terminal AF-2
domain (N/C interaction) prevented toxicity and AR aggre-
gation in an SBMA cell model and rescued primary SBMA
motor neurons from 5-dihydrotestosterone-induced toxic-
ity. Moreover, genetic mutation of the FXXLF motif pre-
vented AR aggregation and 5-dihydrotestosterone toxicity.
Finally, selective androgen receptor modulators, which pre-
vent the N/C interaction, ameliorated AR aggregation and
toxicity while maintaining AR function, highlighting a novel
therapeutic strategy to prevent the SBMA phenotype while
retaining AR transcriptional function.
Spinal and bulbar muscular atrophy (SBMA)2 is an X-linked,
slowly progressive, adult onset, neurodegenerative disease that
primarily affects males. Symptoms include proximal limb
weakness and muscle atrophy, fasciculations, tremor, dyspha-
gia, and dysarthria (1). SBMA results from expansion of a poly-
morphic trinucleotide (CAG) repeat that encodes a polyglu-
tamine (polyQ) tract near the amino terminus of the androgen
receptor (AR) (2). Although many patients exhibit signs of
androgen insensitivity, including gynecomastia, testicular atro-
phy, and infertility, loss ofAR function is not the primarymech-
anistic basis for disease in SBMA (3). Rather, the presence of an
expanded polyglutamine tract within the AR leads to its mis-
folding, aberrant cleavage, and accumulation (4, 5), although
how these phenomena lead to neuronal dysfunction and death
is unclear.
SBMA is a member of a family of nine neurodegenerative dis-
eases caused by an expanded polyglutamine tract; these include
spinocerebellar ataxia types 1, 2, 3, 6, 7, and 17, dentatorubral pal-
lidoluysian atrophy, and Huntington disease (reviewed in Ref. 6).
In addition to neuronal loss, a common pathogenic feature of this
family of neurodegenerative diseases is the accumulation of mis-
folded and aggregated mutant protein in the affected neuronal
populations. SBMA is characterized by the specific loss of lower
motor neurons from the brainstemand anterior horn of the spinal
cord (7). This neuronal loss, the formation of nuclear inclusions,
and the subsequent symptoms of the disease depend on the bind-
ing of the polyglutamine-expanded AR to its ligands testosterone
or 5-dihydrotestosterone (DHT) (8–11).
The AR is a transcription factor and amember of the nuclear
receptor superfamily that is regulated by hormone binding.
Unliganded AR is found in the cytoplasm in an aporeceptor
complex that contains heat shock proteins (Hsc70, Hsp40, and
Hsp90), p23, and immunophilins (12). Androgens such as tes-
tosterone andDHTbindwith high affinity to theAR, causing its
release from the aporeceptor complex. Upon release, the AR
undergoes several conformational changes; one such change is
the interdomain interaction between the 23FQNLF27motif near
the amino terminus and theAF2 domain near the ligand-bound
carboxyl terminus (13–18). Of note, this 23FQNLF28 motif lies
in close proximity to the polyglutamine tract, which begins at
amino acid 58. The amino/carboxyl (N/C) interaction stabilizes
the AR, enhances hormone binding (14, 19), and provides a
binding face for coactivator recruitment (19).
The cellular pathways and molecular mechanisms that give
rise to neuronal dysfunction and cell death in polyQ diseases
remain poorly understood. Polyglutamine length has been
shown to determine the rate of inclusion formation (20) and,
in the case of AR, modulates the folding and structure of the
amino-terminal domain (21). Generally, there appears to be a
pathological threshold of 36–40 glutamines that favors a con-
formational change from a random coil to a -structure (22).
Studies indicate that small monomeric or oligomeric species,
consisting largely of -sheet structures, are cytotoxic to neu-
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rons and lead to neuronal dysfunction (23). It is unclear
whether a single misfolded polyglutamine monomer can pro-
vide a “seed” to induce aggregation through its ability to self-
associate or whether sequences outside of the glutamine tract
are required to promote this interaction. An expanded polyQ
ataxin-1 deletion of a self-association domain outside of the
polyglutamine tract inhibited aggregation but did not amelio-
rate disease (24). Moreover, recent studies reveal a role for the
amino-terminal 17 amino acids of the Huntingtin protein in its
aggregation (25, 26). Finally, although -synuclein does not
have an expanded polyglutamine tract, it self-associates through
an intramolecular interaction (27). This interaction stabilizes the
protein conformation of -synuclein by masking one of its own
domains, the highly amyloidogenic NAC (non-A component of
Alzheimer disease amyloid) domain, frompromoting aggregation
(27, 28).
We sought to determine whether a similar interaction of
expanded polyQARplays a role in toxicity and aggregation.We
utilized various ligands of AR that inhibit the N/C interaction
induced by testosterone orDHT, aswell as geneticmutations of
the 23FQNLF27 motif that inhibit the N/C interaction, to deter-
mine whether the N/C interaction was required for the altered
metabolism and toxic effects of the expanded polyQ AR. Our
results demonstrate that both pharmacologic and genetic dis-
ruption of the N/C interaction of expanded polyQ AR prevent
inclusion formation and toxicity of mutant AR in models of
SBMA. Moreover, we show that phosphorylation of the AR at
both Ser-81 and Ser-308 is dependent upon this interdomain
interaction, demonstrating the utility of using this phosphoryla-
tion status to mark this disease-associated structural feature.
EXPERIMENTAL PROCEDURES
Construction of Mutant AR Cell Lines—FXXLF mutant
AR-expressing PC12 cells were constructed by excision of
pCMVhAR-F23A and pCMVhAR-L26A/F27A plasmids with
NheI/NarI and ligation of each mutated fragment into both
pTREAR10Q and pTREAR112Q plasmids. Mutation of
Ser-81 and Ser-308 to alanine was performed by sequential
site-directed mutagenesis (QuikChange II, Stratagene) of
pTREAR112Q. All mutations and CAG lengths were sequence-
verified. Transfection of tet-On PC12 cells (Clontech, Mountain-
view, CA) was performedwithmutant pTREAR plasmids and the
hygromycin-resistant plasmid pTK-Hygro using calcium phos-
phate.Transfectedcellswere selectedby theadditionof200g/ml
hygromycin (Invitrogen). Single colonies were isolated, expanded,
and screened for AR protein expression by inducing AR with 1
g/ml doxycycline (Clontech); positive clones were verified via
slot-blot and immunoblotting with the antibody ARN20 (Santa
CruzBiotechnology, SantaCruz,CA).GenomicDNAwas isolated
from positive clones, and both the mutation(s) and CAG repeat
lengthwere verifiedbyPCRand sequencing.The amount of doxy-
cycline required to induce a level of AR protein expression com-
parable with that in the pTREAR112Q cell line was determined.
Cell Culture and Reagents—Stable PC12 cells inducibly
expressing AR were maintained as described (11). All experi-
ments were performed in media that contained charcoal-
stripped serum (stripping protocol from Sigma). Cells contain-
ing AR10Q and AR112Q were induced with 10 or 500 ng/ml
doxycycline (Clontech). All other cell lines were induced to
express equivalent amounts of AR to AR10Q and AR112Q.
DHT (Sigma) and bicalutamide (Toronto Research Chemicals,
North York, Ontario, Canada) were resuspended in EtOH.
Primary Motor Neuron Cultures—Dissociated spinal cord
cultures were established according to Roy et al. (29). Spinal
cords were held on ice during rapid PCR genotyping, and spinal
cords of nontransgenic or AR112Qwere then pooled, plated on
poly-D-lysine-coated glass coverslips in 24-well plates, and
cultured for 3 weeks in glia-conditioned media containing
minimal essential medium, 3% charcoal-stripped horse
serum, 35 mM NaHCO3, 0.5% dextrose, 1% N3, and 10 nM
2.5S nerve growth factor. After 3 weeks, cultures were
treated with DHT or other AR ligands as indicated. After 7
days, cellswere fixedand immunostained forneurofilamentheavy
chain with SMI32 as described below, and 10 random fields of
motor neurons (determined by size and morphology) were
counted.A two-wayANOVA/post-hocTukey testwasperformed
using SigmaStat software (SPSS, Inc., San Jose, CA).
Biochemical Analysis—Cells were harvested on ice with cold
PBS, and cell pellets were lysed with immunoprecipitation
assay buffer or Triton-DOC buffer (containing 100 g/ml
PMSF, 0.2 mM sodium orthovanadate, 2 nM okadaic acid
(Calbiochem), and phosphatase substrate (Sigma)) and son-
icated. Western analysis was performed using a standard
protocol for antibodies ARN20, AR441, ARH280, GAPDH
(Santa Cruz Biotechnology), and NCL-AR-318 (NovoCastra
Laboratories Ltd., Newcastle Upon Tyne, United Kingdom)
or AR(p)Ser81 (Millipore, Billerica, MA) and AR(p)Ser308
(Santa Cruz Biotechnology). Filter trap analysis was performed
as described (30).
Immunofluoresence—PC12 cells and primary neuron cul-
tures were fixed and stained as described previously (31). Anti-
bodies included ARN20, ARH280, AR441 (1:100) (Santa Cruz
Biotechnology), and SMI32 (1:1000) (SternbergerMonoclonals
Inc., Baltimore). Cells were visualized with a Leica microscope
(Leica Microsystems GmbH, Wetzler, Germany), and images
were captured with a Leica camera and analyzed with iVision-
MacTM software (BioVision Technologies, Exton, PA). In PC12
cells, the percentage of inclusions was determined by counting
at least 1000 cells averaged from three independent wells; sta-
tistical analysis was performed with SigmaStat software using a
one-way ANOVA/post-hoc Tukey test. Experiments were
repeated at least three times.
PC12 Cell Toxicity Assay—The toxicity of PC12 cell lines
(AR10Q, AR112Q, AR110Q-F23A, and AR110Q-L26A/F27A)
was analyzed as described previously (31). Three independent
experiments were performed in triplicate, and statistical signif-
icance was determined by SigmaStat using a one-wayANOVA/
post-hoc Tukey test.
Protein Stability Assays—AR expression was induced with
doxycycline in PC12 cell lines (AR112Q, AR110Q-F23A, and
AR110Q-L26A/F27A) for 48 h. Cells were then washed three
times with PBS to remove media containing doxycycline and
treated with media containing 30 g/ml cycloheximide and
EtOH or 10 nM DHT. Cells were harvested at the given times
after media replacement. AR levels were determined by West-
ern analysis. Films were scanned, and densitometry was cal-
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culated using Kodak 1D image analysis software (Eastman
Kodak Co.).
Mammalian Two-hybrid Assay—HEK293 cells were seeded
at 1.6  105 in 12-well plates in antibiotic-free DMEM supple-
mentedwith 10% fetal bovine serum
and 2 mM L-glutamine. Cells were
transfected using Lipofectamine
2000 (Invitrogen) in Opti-MEM
with fusion constructs consisting
of VP16-AR111Q (amino acids
12–660) and GAL4DBD-AR (amino
acids 624–919). The interaction
between the two encoded proteins
activates the co-transfected GAL4-
driven luciferase reporter, and
expression wasmonitored in a dual-
luciferase system (Promega, Madi-
son, WI). A co-transfected con-
struct encoding Renilla luciferase
was used to normalize transfection
efficiency. The cells were washed
12 h after transfection, and the
mediumwas replaced with charcoal
serum-stripped DMEM containing
EtOH, DHT, or bicalutamide (per-
formed in triplicate). After a 48-h
incubation, cells were lysed and
luciferase activity was measured on
a luminometer according to the
manufacturer’s instructions. The
ratios of firefly luciferase to Renilla
luciferase activity from quadrupli-
cate samples were averaged and
normalized to DHT-treatment,
which was set to 100. Significance




Bicalutamide Alters Nuclear In-
clusion Formation and Prevents
DHT-dependent Toxicity in PC12
Cells—Using rat adrenal gland-de-
rived PC12 cells, we previously cre-
ated an inducible cell model of
SBMA that, upon addition of doxy-
cycline, expresses full-length human
AR with an expanded polyglutamine
tract (112Q)and, in response toDHT,
forms nuclear inclusions of AR (11).
This cell model recapitulates the his-
topathology of SBMA motor neu-
rons, inwhich intranuclear inclusions
consist primarily of proteolyzed ami-
no-terminal fragments of AR3 (5, 32)
(Fig. 1A). Using this SBMA cell
model,wewanted to assess the effects
that other AR ligands might have on the altered metabolism of
expanded polyQAR.We treated AR10Q- or AR112Q-expressing
3 E. Heine and D. E. Merry, unpublished results.
FIGURE 1. Bicalutamide prevents nuclear inclusions in a cell model of SBMA. Stably transfected PC12 cells
were induced with 10 ng/ml doxycycline to express AR10Q or AR112Q for 96 h. Cells were treated with EtOH,
0.01 M DHT, or 0.01, 0.1, or 10 M bicalutamide. A, cells were fixed and immunostained with an antibody to the
amino terminus of AR (AR-N20), an antibody (AR-441) detecting a more internal epitope of AR (amino acids
299 –315), and Hoechst to reveal nuclei. Panels depict cells treated with 0.01 M DHT or 10 M bicalutamide.
B, 1000 cells were counted for each treatment, in triplicate. The number of cells with ARN20-staining inclusions
was averaged, expressed as a percentage of total cells, and graphed. One-way ANOVA was performed (***, p 
0.001; **, p  0.01; *, p  0.05). C, AR112Q cells were treated alone or in combination with EtOH, 0.01 M DHT,
and 10 M bicalutamide for 96 h. Inclusions were counted as in B. One-way ANOVA was performed: *, p  0.001.
These findings are representative of three independent experiments. D, bicalutamide does not induce inclu-
sions of a constitutively nuclear expanded polyQ-AR. AR112Q or NLSx3-AR76Q-expressing cells were treated
for 48 h with EtOH, 0.01 mM DHT, or 10 mM bicalutamide. Over 1000 cells were counted/well, and the percent-
age of cells containing inclusions was averaged and graphed. One-way ANOVA was performed (*, p  0.001).
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cells with DHT or increasing amounts of bicalutamide for 4 days.
Immunofluorescence analysis revealed that DHT caused the for-
mation of nuclear inclusions containing only amino-terminal AR
epitopes (ARN20-positive, AR441-negative) in AR112Q but not
AR10Q-expressing cells, as expected (Fig. 1A). High concentra-
tions (10M) of the nonsteroidal compound bicalutamide, a tran-
scriptional antagonist of the AR, failed to induce the formation of
nuclear inclusions inAR112Q-expressingcells,despitenuclearAR
localization (Fig. 1A), whereas comparably high concentrations of
DHTinducedsubstantial aggregation(Fig.6Banddatanot shown)
similar to that inducedby lowconcentrations ofDHT.Lower con-
centrations (0.01 and 0.1 M) of bicalutamide induced inclusions
at low frequency (Fig. 1B). In addition, bicalutamide reduced AR
inclusions even in the presence of DHT (Fig. 1C). Biochemical
analysis also revealed a reduction of highmolecularweight species
when cells were exposed to bicalutamide, either alone or in the
presenceofDHT(Fig. 2B), supporting aneffect of bicalutamideon
aggregation.
DHT treatment of AR112Q-expressing cells not only caused
the formation of nuclear inclusions (Fig. 1A) but also resulted in
significant and substantial cell death (Fig. 2A). We then deter-
mined whether bicalutamide would cause toxicity and
whether it could prevent the DHT-induced toxicity caused
by expanded polyQ-AR. Bicalutamide failed, when used
alone, to cause toxicity in these cells (Fig. 2A). Moreover,
combined treatment with bicalutamide and DHT resulted in
substantial and significant protection from DHT-induced
toxicity. These data indicate that bicalutamide is capable of
rescuing AR112Q-expressing PC12 cells from the toxic
effects of DHT.
We next evaluated AR protein levels in cells treated with
bicalutamide. Biochemical analysis revealed that although
bicalutamide alone did not stabilize the AR, it did not alter AR
stabilization by DHT (Fig. 2B), indicating that the mechanism
by which bicalutamide prevented DHT-induced toxicity was
not through loss of AR protein stability. Moreover, the lack of
stabilization of AR112Q was observed only with the highest
concentration of bicalutamide when used alone; low levels of
bicalutamide, which partially stabilized AR112Q (data not
shown), also decreased inclusions (Fig. 1B) and toxicity (data
not shown). Thus, these data support the conclusion that
bicalutamide impacts AR aggregation and toxicity indepen-
dently of effects on AR stability.
Although immunostaining of PC12 cells expressing AR in
the presence of bicalutamide indicated that this ligand induced
nuclear localization of expanded polyQ AR, we sought to rule
out the possibility that bicalutamide reduced nuclear inclusions
by delaying the transit of AR into the nucleus. To this end, we
utilized PC12 cells expressing expanded AR (76Q) with an
exogenous nuclear localization signal (NLSX3) fused to the
amino terminus; in these cells, both unliganded and liganded
AR is confined to the nuclear compartment (31). Treatment of
NLSX3-AR76Q-expressing cells with bicalutamide resulted in
a substantial reduction of the number of cells with nuclear
inclusions compared to treatmentwithDHT(Fig. 1D), indicating
that bicalutamide inhibits mutant AR aggregation and toxicity
independently of any potential effect on nuclear translocation.
Bicalutamide Prevents DHT-dependent Toxicity in Primary
SBMA Motor Neurons—We next investigated the effect of
bicalutamide on SBMA motor neuron viability. Motor neuron
toxicity assays were performed on dissociated spinal cord cul-
tures derived from transgenic SBMAmouse embryos (Fig. 3A).
This transgenic mouse model of SBMA expresses full-length
AR with a polyglutamine tract 112 amino acids in length and
recapitulates the gender-specific motor deficits and intranu-
clear inclusions of SBMA (8). Motor neuron cultures derived
from these mice reproduce the hormone-dependent AR aggre-
gation and toxicity observed in SBMA (31, 33). Treatment of
3-week-old differentiated spinal cord cultures with DHT
resulted in the loss of 35% of the motor neurons (Fig. 3B) as
observed previously (31, 33). In contrast, bicalutamide not only
failed to induce motor neuron death but also prevented DHT-
induced toxicity (Fig. 3B). Moreover, qualitative comparisons
of neurofilament heavy chain staining revealed that treatment
with DHT, but not bicalutamide, resulted in reduced unphos-
phorylated NF-H immunostaining (Fig. 3A), as seen in vivo (8).
In addition, DHT-treated axons appeared thinner and shorter,
suggesting reduced neuronal health. Bicalutamide appeared to
produce a qualitative improvement in these features (Fig. 3A,
right panel).
Bicalutamide Alters Phosphorylation of Expanded PolyQ AR—
Having established that bicalutamide prevented bothARaggre-
gation and toxicity in our PC12 cellmodel of SBMAaswell as in
transgenic SBMA motor neurons, we next explored the possi-
FIGURE 2. Bicalutamide prevents DHT-induced toxicity in an SBMA cell
model. A, stably transfected PC12 cells were induced with 500 ng/ml doxy-
cycline to express AR112Q for 12 days. Cells were treated with EtOH, 0.01 M
DHT, 10 M bicalutamide, or bicalutamide in the presence of DHT. Cells were
harvested and stained with trypan blue, and at least 300 cells were counted in
triplicate. Two-way ANOVA was performed (*, p  0.001). B, Western analysis
was performed on protein lysates of AR112Q induced with 500 ng/ml doxy-
cycline and treated with EtOH or 0.01 M DHT in the presence or absence of 10
M bicalutamide for 48 h. Comparable results were obtained from cells
treated for 12 days (data not shown).
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ble mechanism for these effects. It is known that DHT binding
to the AR induces a conformational change that results in the
phosphorylation of numerous residues within the AR (34–37).
It has been shown previously that bicalutamide prevents phos-
phorylation of normal polyQ AR at Ser-81 (38). We therefore
examined whether bicalutamide would alter the phosphoryla-
tion of Ser-81 on expanded polyQ
AR. Western analysis of AR112Q-
expressing PC12 cells revealed that
bicalutamide failed to induce, to the
same level as DHT, the phosphory-
lation of both Ser-81 and Ser-308
(Fig. 4A, left), and it reduced the
phosphorylation of both residues
even in the presence of DHT (Fig.
4A, right). Moreover, we observed
that phosphorylation of Ser-81 was
enhanced by polyglutamine expan-
sion (Fig. 4B). We therefore rea-
soned that phosphorylation of one
or both of these residues might be
linked to the ability of the mutant
AR to form inclusions. To test this
hypothesis, we mutated Ser-81 to
alanine to prevent its phosphoryla-
tion, either alone (S81A) or in com-
bination with a mutation of Ser-308
(S81A/S308A). The phosphoryla-
tion-null mutant neither of Ser-81
nor of Ser-81/Ser-308 had any effect
on the frequency of nuclear inclu-
sion formation (data not shown),
demonstrating that alteration of
phosphorylation at these sites is not
the primary mechanism by which
bicalutamide prevents inclusions.
Bicalutamide Disrupts the N/C Interaction of Polyglutamine-
expanded AR—Bicalutamide has been shown to prevent the
interdomain interaction between the amino and carboxyl AR
termini (39, 40) that occurs upon agonistic androgen binding
(13). To confirm that this is also the case for an expanded
polyQ-AR, we monitored the interaction of the amino and car-
boxyl termini of the polyglutamine-expanded AR (111Q) using
a mammalian two-hybrid assay. Cells were transfected with a
construct encoding the VP16 activation domain fused to the
amino terminus of AR (amino acids 12–660) and a construct
encoding theGAL4DNA-binding domain fused to the carboxyl
terminus of AR (amino acids 624–919). The interaction of
these fusion proteins was monitored by their ability to activate
a luciferase reporter under the control of Gal4 regulatory
sequences. Co-transfection with a Renilla luciferase plasmid
was used to control for transfection efficiency. As expected, in
contrast to the substantial N/C interaction of expanded polyQ
AR upon DHT binding, there was minimal N/C interaction in
both the absence of ligand and the presence of bicalutamide
(Fig. 5A). An examination of the effect of bicalutamide on
expanded polyQ AR N/C interaction in the mammalian two-
hybrid system revealed that low levels of bicalutamide induced
a significant N/C interaction (albeit still lower than that caused
by DHT binding) (Fig. 5A). The extent of N/C interaction
induced by bicalutamide was correlated with both the fre-
quency of inclusions (Fig. 1B) and the level of AR phosphory-
lation at serines 81 and 308 (Fig. 4A), consistent with a role for
the N/C interaction in these events. We next examined the
FIGURE 3. Bicalutamide prevents DHT-induced toxicity in primary motor neuron cultures of SBMA mice.
After 3 weeks of differentiation, dissociated spinal cord cultures were treated for 7 days with EtOH or 10 M DHT
in the presence or absence of 10 M bicalutamide (Bic). A, cells were fixed and immunostained with the
antibody SMI-32 (unphosphorylated neurofilament heavy chain) and then stained with Hoechst. B, counts
were obtained from 10 random fields at 20 under a Leica microscope from three separate wells of each
treatment of motor neurons and then graphed. Two-way ANOVA was performed with post-hoc Tukey test
(*, p  0.001).
FIGURE 4. Bicalutamide and polyQ length alter phosphorylation of AR.
A, left, Western analysis was performed on protein lysates obtained from
AR112Q-expressing cells treated in the presence or absence of 0.01 M DHT
or 0.01, 0.1, or 10 M bicalutamide. Protein lysates were loaded to achieve
equivalent AR levels. Right, bicalutamide reduced phosphorylation of Ser-81
and Ser-308 even in the presence of DHT. B, left, Western analysis was per-
formed on protein lysates obtained from AR10Q- and AR112Q-expressing
cells treated with EtOH or 50 M DHT. The panels of AR10Q and AR112Q came
from the same Western blot. Right, the Ser-81 phosphorylation state of the AR
was unaffected by DHT concentration. Western analysis was performed on
protein lysates obtained from AR112Q-expressing cells treated in the pres-
ence of either 0.01 or 50 M DHT for 96 h. The membranes were probed with
antibodies for phosphorylated Ser-81 (AR (P)Ser81) or phosphorylated Ser-
308 (AR(P)Ser308) and pan-AR (-AR) (AR-H280 (A) or AR-N20 (B)).
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effect of bicalutamide in the presence of DHTon theN/C inter-
action ofAR. Bicalutamide substantially prevented the ability of
AR to formanN/C interaction in the presence ofDHT (Fig. 5B).
This correlated with the reduction of inclusions (Fig. 1C) and
the prevention of DHT-induced toxicity (Fig. 2A).
Genetic Disruption of the N/C Interaction of AR Prevents
Nuclear Inclusions and Toxicity—To directly test the hypothe-
sis that the N/C interaction plays a role in the altered metabo-
lism of expanded polyQAR, we utilized two separatemutations
of the 23FQNLF27 motif at the amino terminus of the AR, pre-
viously shown to disrupt the interdomain interaction (14). We
confirmed the effect of FXXLFmutation on theN/C interaction
of expanded polyQ AR by utilizing the mammalian two-hybrid
assay. Two distinct mutations of the 23FQNLF27 motif (F23A
and L26A/F27A) disrupted the N/C interaction of an expanded
polyQAR in the presence of DHT (Fig. 6A). To test the effect of
these mutations on expanded AR aggregation and toxicity, we
made stable inducible PC12 cell lines containing either the sin-
gle (F23A) or the double (L26A/F27A) FXXLF mutation in
expanded polyQ AR. Cells expressing either of the FXXLF
mutant AR proteins showed nuclear localization of the mutant
AR in response toDHT (data not shown). Immunofluorescence
analysis of these cell lines following DHT treatment showed a
substantial reduction in nuclear inclusions (Fig. 6B), despite
comparable AR protein levels (data not shown). Earlier studies
indicated that the N/C interaction contributes to the stabiliza-
tion of ligand binding (13). To rule out the possibility that the
effect of FXXLF mutation on inclusion frequency was second-
ary to changes in ligand binding, we tested the effects of the
FXXLF mutations using higher DHT concentrations. Regard-
less of DHT concentration (up to 50 M), mutation of the
FXXLF motif substantially abrogated the formation of AR
nuclear inclusions (Fig. 6B).
We next sought to determine whether the FXXLFmutations
could prevent DHT-dependent toxicity of expanded polyQ
AR. As expected, we observed DHT-dependent toxicity of
FIGURE 5. Bicalutamide prevents the N/C interaction of polyQ-expanded
AR. Mammalian two-hybrid assay was performed by transfecting HEK293
cells with the N-terminal AR111Q (amino acids 12– 660) fused to a VP16 acti-
vation domain, the C-terminal AR (amino acids 624 –919) fused to the Gal4
DNA-binding domain, the Gal4-luciferase reporter, and the Renilla-luciferase
transfection control plasmid. Dual-luciferase activity was determined from
cell lysates. A, cells were treated in triplicate with EtOH, 0.01 M DHT, or
increasing amounts of bicalutamide (0.01, 0.1, or 10 M) for 48 h. The values
obtained from the ratios of Gal4-Luc/Renilla-Luc were normalized to the value
of DHT-treated AR111Q set to 100. One-way ANOVA was performed (*, p 
0.001). The findings are representative of three independent experiments.
B, cells were treated with EtOH or 0.01 M DHT alone or in combination with
10 M bicalutamide for 48 h. The values obtained from the ratios of Gal4-Luc/
Renilla-Luc were normalized to the value of DHT-treated AR111Q set to 100.
One-way ANOVA was performed (*, p  0.001). The findings are represen-
tative of three independent experiments.
FIGURE 6. Mutation of the FXXLF motif of AR polyQ-expanded AR pre-
vents the N/C interaction, nuclear inclusions, and toxicity in an SBMA cell
model. A, mammalian two-hybrid assay was performed as described in the
legend for Fig. 5, including the AR111Q-F23A or ARQ111-L26A/F27A mutant
fused to a VP16 activation domain. Student’s t test was performed (*, p 
0.01). B, stably transfected PC12 cells were induced to express equivalent
levels of AR10Q, AR112Q, AR110Q-F23A, or AR110Q-L26A/F27A. Cells were
treated with increasing amounts of DHT (0.01, 1.0, and 50 M) for 48 h, fixed,
and immunostained as in Fig. 1A. Over 1000 cells were counted, and the
percentage of cells containing nuclear inclusions graphed. Student’s t test
was performed (*, p  0.02). C, toxicity was assessed as in Fig. 2A. Two-way
ANOVA was performed (**, p  0.001;*, p  0.01). The findings are represent-
ative of three independent experiments.
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expanded AR compared with a normal polyQ AR (Fig. 6C).
However, DHT failed to induce toxicity of both F23A- and
L26A/F27A-expressing cells (Fig. 6C), indicating that an intact
FXXLF sequence is required for DHT-dependent, polyQ-de-
pendent toxicity.
It was previously shown that the FXXLF motif may contrib-
ute to the regulation of AR degradation (41, 42). Although we
inducedARexpression in themutant cell lines to produce levels
of FXXLF mutant AR equivalent to that of AR112Q (wild type
for the FXXLF motif), we questioned whether the mutation
altered the stabilization of the AR by hormone. Treatment with
epoxomicin to inhibit the proteasome revealed the accumula-
tion of both ARmutant proteins, indicating that these proteins
continued to be degraded by the proteasome (data not shown).
We also carried out half-life analysis of AR protein, quantifying
ARprotein at time points followingwashout of doxycycline and
in the presence of cycloheximide. This analysis indicated that,
although the mutation of Leu-26/Phe-27 decreased the turn-
over of both unliganded and liganded expanded AR, mutation of
Phe-23 had no effect on unliganded AR turnover and a modest,
destabilizing effect on liganded AR (Fig. 7). Given the similar
effects of these mutations on AR aggregation and toxicity, it is
unlikely that turnover, as regulated by the FXXLF motif of the
mutantAR, plays amajor role in the cytoprotective effects of these
mutations. Taken together, these results suggest that FXXLF
mutation abrogates expanded polyQ AR aggregation and toxicity
largely because of disruption of the interdomain N/C interaction.
Selective ARModulators (SARMs) That Prevent N/C Interac-
tion Also Prevent AR Aggregation and Toxicity—We next
sought to determine whether additional AR ligands, selected to
inhibit the N/C interaction, could prevent AR aggregation and
toxicity. Two such ligands, derived from the chemical backbone
of RU486 (40), failed to induce the AR N/C interaction (Fig.
8A). Despite the lack of N/C interaction, these ligands stimu-
lated AR transcription on an MMTV promoter (Fig. 8B).
Although theMMTVpromoter shows little dependence on the
N/C interaction for activity (43, 44), SARMs of the RTI class
have been shown to exhibit a range of partial to complete ago-
nist activities on a non-MMTV reporter (40) and on endoge-
nous gene promoters (44). Both RTI-016 and RTI-051b pro-
moted the nuclear translocation of AR, as expected (data not
shown). However, both SARMs failed to induce AR inclusions
to the extent seen in the presence of DHT (Fig. 8C). Moreover,
filter trap analysis revealed that, although DHT induced sub-
stantial filter-trapped aggregated AR, the two alternative
ligands shown here failed to induce AR aggregation to a similar
extent (Fig. 8D). Finally, we tested the ability of these two
selected SARMs to induce AR112Q toxicity in SBMA motor
neurons. Unlike DHT, both RTI-016 and RTI-051b failed to
induce toxicity (Fig. 9). Thus, not only does the AR antagonist
bicalutamide fail to inducemutantAR aggregation and toxicity,
but two structurally unrelated AR ligands also fail to induce AR
aggregation and toxicity, further implicating the importance of
the N/C interaction in both aspects of SBMA pathology. More-
over, the identification of AR ligands that prevent toxicity even
while functioning as partial or complete transcriptional ago-
nists provides a novel approach to the development of thera-
peutic compounds for SBMA.
Phosphorylation Is a Marker for the N/C Interaction of AR—
We showed that bicalutamide failed to induce substantial phos-
phorylation of both Ser-81 and Ser-308 (Fig. 4A). To determine
whether this result was specific to bicalutamide-bound AR or
resulted from the disruption of the N/C interaction of AR, we
performed Western analysis of phosphorylation of the genetic
mutants AR110Q-F23A and AR110Q-L26A/F27A. We found
that phosphorylation of both Ser-81 and Ser-308 was absent
when the N/C interaction was genetically disrupted (Fig. 10A),
demonstrating that an intact FQNLFmotif is required for phos-
phorylation at these residues. Finally, we assayed phosphoryla-
tion of these sites upon treatment of AR112Q cells expressing the
expandedpolyQARwithSARMsknown todisrupt theN/C inter-
action. Consistent with our previous results, we found that treat-
ment with SARMs that prevent theN/C interaction disrupted the
phosphorylation of serines 81 and 308 (Fig. 10B). These data indi-
cate that the interdomainN/Cinteraction is required forphospho-
rylation of serines 81 and 308 and that these post-translational
modifications can be used to report on the N/C interaction.
DISCUSSION
The roles of both hormone binding and nuclear localization
of the mutant, polyglutamine-expanded AR have been estab-
lished as essential components of the pathogenic process in
SBMA (8–11, 31). However, additional details of the patho-
genic metabolism of the AR that leads to its toxicity remain
obscure. Our studies presented here focused on this question,
in an effort to identify upstream steps in the pathogenic process
that can be targeted for therapeutic benefit. To this end, we
have identified a step in the normal metabolism of AR, a con-
formational change involving the N/C interaction, as a critical
step in mutant AR aggregation and toxicity.
In our analysis of the effect of AR antagonistic ligands, we
found that the nonsteroidal AR antagonist bicalutamide
reduced mutant AR nuclear inclusion formation and DHT-de-
pendent toxicity in a PC12 cell model of SBMA. Moreover,
FIGURE 7. Effect of FXXLF mutation on AR protein half-life. Stably trans-
fected PC12 cells were induced to express equivalent levels of AR112Q,
AR110Q-F23A, or AR110Q-L26A/F27A for 48 h. After 48 h of doxycycline
induction and EtOH or 0.01 M DHT treatment, the cells were washed with
PBS to remove doxycycline, and 30 g/ml cycloheximide with EtOH or DHT
was added. Cells were harvested at various time points, and Western analysis
was performed on protein lysates. Blots were probed with pan-AR (AR-H280)
and GAPDH antibodies. Densitometry was performed on the film, and the
ratio of AR/GAPDH was graphed for each cell line. The findings are represent-
ative of three independent experiments.
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bicalutamide treatment prevented DHT-induced toxicity in
primary motor neurons derived from SBMA mice. Bicalut-
amide affects AR metabolism in multiple ways, including
changes in AR phosphorylation, turnover, DNA binding,
recruitment of transcriptional coregulators and the interaction
between the amino and carboxyl termini of AR.
Bicalutamide was shown previously to prevent phosphoryla-
tion of theAR at Ser-81 (38). This observation, coupledwith the
ability of bicalutamide to ameliorate inclusions and toxicity of
expanded polyQAR, suggested that phosphorylation at this site
might play a role in SBMA pathogenesis. However, our finding
that the phosphorylation-null mutations of Ser-81 and of Ser-
308 failed to impact expanded AR aggregation indicates not
only that phosphorylation of Ser-81 and Ser-308 are not essen-
tial components of the pathogenic pathway in SBMA but also
that prevention of phosphorylation of these sites is not the
mechanism by which bicalutamide ameliorates the abnormal
metabolism of expanded polyQ AR.
FIGURE 8. SARMs that do not reduce the AR N/C interaction but promote AR transcriptional activity fail to induce aggregation of expanded polyQ AR
in an SBMA cell model. A and B, HepG2 cells were transfected with plasmids for mammalian two-hybrid analysis (A) and transcriptional activity (B). For AR
mammalian two-hybrid assays, the DNA transfected into the cells consisted of pcDNA-AR1-660, VP16-AR507-919, MMTV-Luc, and pCMV-Gal. For AR tran-
scriptional assay, the DNA consisted of pSG5-AR, MMTV-Luc, and pCMV-Gal. Cells were treated with hormone for 48 hr, lysed, and firefly luciferase (reporter)
and -galactosidase (transfection normalization) assays performed. C and D, stably- transfected PC12 cells were induced with 1 g/ml of doxycycline to express
AR112Q for 48 hr. Cells were treated with EtOH, DHT (50 M) or various concentrations of RTI-016 and RTI-051b. C, cells were fixed and immunostained with an
antibody to the N terminus of AR (AR-H280), an antibody (AR-441) detecting a more internal epitope of AR (amino acids 299-315), and Hoechst. One thousand cells
were counted for each treatment in triplicate. The number of ARN20-staining inclusions was averaged, expressed as a percentage of total cells, and graphed. Student’s
t test was performed. *  p  0.05; **  p  0.01; ***  p  .005. D, insoluble androgen receptor protein was detected using filter trap analysis. Protein lysates
of treated cells were pulled by vaccum through cellulose acetate. The membrane was probed with an antibody for the N terminus of AR (AR-H280).
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We also observed that a high dose of bicalutamide reduced
AR protein levels, suggesting that reductions in AR protein
were responsible for the decrease in both nuclear inclusions
andAR toxicity.Moreover, a previous study had shown, in con-
trast to our results, that bicalutamide induced toxicity in pho-
toreceptor neurons of a fly model of SBMA without reducing
AR levels (45). It may be that the effective dose in fly photore-
ceptors was substantially lower than the dose causing increased
AR turnover in our studies. However, we found an amelioration
of toxicity and AR aggregation even at lower doses of bicalut-
amide. Thus, whether the different effects of bicalutamide in
that study (45), comparedwith the studies reported here, reflect
only a potential difference in dose or are also related to differ-
ences in AR metabolism between the invertebrate model and
our mammalian models is currently unknown. Nonetheless, in
our studies, bicalutamide also decreased AR aggregation (Fig.
1C) and toxicity (Fig. 2A) in the presence of DHTwithout alter-
ing AR protein levels (Fig. 2B), indicating that effects on AR
turnover are not solely responsible for the bicalutamide rescue
of DHT-dependent AR toxicity. Moreover, lower concentra-
tions of bicalutamide, which similarly had no effect on AR pro-
tein levels, also decreased expanded AR toxicity in the presence
of DHT (data not shown).
An earlier study (46) of the effect of androgen ablation on
disease in mutant AR transgenic mice included an analysis of
flutamide, a bicalutamide-related AR antagonist that also pre-
vents the N/C interaction, albeit with lower AR affinity and
potency. Flutamide failed to impact disease onset or progres-
sion in these mice and had no effect on AR aggregation (46).
However, whether the dose used in that study allowed effective
levels to be achieved in the nervous system is unknown.
The binding of androgens to the AR initiates a set of confor-
mational changes within the AR that result in interdomain
interactions as well as translocation of AR to the nucleus. One
interdomain interaction that is key to both the stabilization of
the AR and its activation to a fully functional transcription factor
occurs between the FXXLF motif at the amino terminus and the
ligand-bound AF-2 motif at the carboxyl terminus (14, 41). This
interaction, in concert with androgen binding, stabilizes the
androgen receptor and recruits coactivators that are important
for the transcriptional activation function of the AR. The bind-
ing of the AR by the antagonist
bicalutamide prevents this interac-
tion. Moreover, the novel agonistic
ligands (SARMs) used in this study
also prevent the N/C interaction.
Thus, our results, using both phar-
macologic and genetic approaches,
demonstrate that the interaction
between the amino and carboxyl
termini of expanded polyQ AR is a
critical and early event essential for
the abnormal metabolism and tox-
icity of the mutant AR.
Although our results showed that
bicalutamide prevented DHT-de-
pendent AR toxicity without im-
pacting AR protein levels, we can-
not rule out a role for protein
degradation in the mechanism by
which the N/C interaction contrib-
utes to disease. It is well known that
DHT binding stabilizes the AR (47),
unlike the effect of hormone bind-
ing by several other steroid hor-
mone receptors. Earlier studies
revealed that the N/C interaction
contributes to this stabilization of
the AR by hormone binding (41).
These findings suggest that inhibi-
FIGURE 9. SARMs fail to induce toxicity in primary motor neurons of
SBMA mice. After 3 weeks of differentiation, dissociated spinal cord cultures
were treated for 7 days with EtOH, DHT, RTI-016, or RTI-051b. Ligands were
used at 10 M concentration. Counts were obtained from analysis using 200
magnification of 10 random fields from three separate wells of each treat-
ment of motor neurons. One-way ANOVA/post-hoc Tukey test was per-
formed (*, p  0.001, compared with all other conditions).
FIGURE 10. Disruption of the AR N/C interaction prevents phosphorylation of serine 81 and serine 308.
A, Western analysis was performed on cell lysates from stably transfected PC12 cells induced to express equiv-
alent levels of AR112Q, AR110Q-F23A, and AR110Q-L26A/F27A and treated with EtOH or 0.01 M DHT for 48 h.
Membranes were probed with antibodies against phosphorylated Ser-81 (AR(P)Ser81) (left) or phosphory-
lated Ser-308 (AR(P)Ser308) (right). Note that the lanes on each Western blot are from the same blot; those shown
on the left are noncontiguous. Membranes were reprobed for pan-AR (AR-N20 or AR-H280) and GAPDH (not shown).
B, AR112Q cells were treated with EtOH, 0.01 M DHT, 0.01, 0.1, 1, or 10 M RTI-016, or RTI-051b for 48 h. Cell lysates
were probed with antibodies detecting AR(P)Ser81, AR(P)Ser308, pan-AR (AR-H280), and GAPDH.
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tion of the N/C interaction would lead to increased turnover
of themutant AR, likely explaining the effect of high-dose bicalu-
tamide on decreasing AR steady-state protein levels. In addi-
tion, we observed that, although the F23A mutation did not
alter the half-life of unliganded AR, it modestly decreased the
half-life of DHT-bound AR (Fig. 7), supporting the idea that
stabilization of theARwith theN/C interactionmay contribute
to its role in disease pathogenesis.
The mechanism by which the N/C interaction leads to AR
stabilization is unknown. However, others have shown effects
of FXXLFmutation on AR stabilization by hormone (41), and a
more recent study suggests that the FXXLFmotif may function
as a degron (42). Thus, the degron function of the FXXLFmotif
may be masked by its binding to the carboxyl terminus within
the N/C interaction. This finding raises questions about the
effect of FXXLF mutation on AR degradation in our studies.
However, although substantial increases in AR protein were
observed upon “triple” mutation of the FXXLF motif
(23AXXAA27) (42), more modest effects were found upon
mutation of only one or two of the conserved amino acids
within this sequence, albeit within the context of a truncated
huntingtin protein. Moreover, these observations suggest that
FXXLF mutation would reduce the efficiency of expanded
(polyQ) AR degradation by the 26S proteasome, resulting in
further accumulation of themutant AR and enhancement of its
toxicity and aggregation. Our studies of FXXLF mutant AR
indicated amodest effect of the F23Amutation onDHT-bound
AR turnover, but bydecreasing (Fig. 7) rather than increasing its
half-life, consistent with a negligible effect on degron function
and a major effect on the N/C interaction. In contrast, the
L26A/F27A mutation led to the modest stabilization of both
unliganded and liganded AR (Fig. 7, data not shown). Nonethe-
less, the finding that 23AXXLF27 and 23FXXAA27 similarly
inhibit AR aggregation and toxicity strongly suggests that the
main effect of thesemutations inmodulating disease pathogen-
esis is through their effects on the N/C interaction.
Interdomain interactions have been shown to be an impor-
tant determinant for regulating the neurotoxicity of another
neurodegenerative disease-causing protein, -synuclein. In the
native state, this interaction masks the exposure of the central,
hydrophobic NAC domain, thus preventing -synuclein aggre-
gation (27, 28). In contrast to findings in -synuclein, we found
that the N/C interaction of the AR contributes to, and substan-
tially impacts, aggregation and toxicity. How this interaction
contributes to toxicity is a matter of speculation. It may be that
the amino-terminal region of the AR contains structural motifs
that may contribute to its role in disease. The amino terminus
of the AR, which includes the polyglutamine tract, has been
shown to contain significant regions of intrinsically disordered
structure (48), and polyglutamine expansion increases the
-helical content of the region (21). The FXXLFmotif itself has
been shown to form an amphipathic -helix that binds to the
AF-2 domain via a primary charge clamp (19). Our demonstra-
tion of a role for this interaction in expanded AR aggregation
and toxicity implicates a distinct conformation of the AR ami-
no-terminal region in its abnormal metabolism. Working
together, an expanded polyQ repeat and the N/C interaction
may promote a highly stable AR structure refractory to its nor-
mal metabolism and/or degradation and render it prone to
aggregation.
Our data reveal that, in addition to having a major impact on
AR aggregation and toxicity, the N/C interaction of expanded
polyQ AR is required for the phosphorylation of the AR on
Ser-81 and Ser-308. Both genetic mutation of the FXXLF motif
and the use of AR ligands that prevent the N/C interaction
confirmed the necessity of the N/C interaction for phosphoryl-
ation of these two sites. Moreover, we noted that low levels of
bicalutamide produced a detectable N/C interaction, Ser-81/
Ser-308 phosphorylation and expanded AR aggregation; all
were decreased with increasing bicalutamide levels, consistent
with a direct relationship between these events. The mecha-
nism by which low bicalutamide levels lead to these events is
under investigation. Thus, phosphorylation of Ser-81 and
Ser-308 represents a useful tool in reporting on the N/C
interaction. This finding also suggests that disruption of the
N/C interaction affects downstream phosphorylation events
that require the interaction with the AR of nuclear kinases or
phosphatases.
Another distinct set of protein interactions with the AR
includes p160 coactivators and chromatin remodeling com-
plexes, which govern the ability of theAR to promote transcrip-
tion. GRIP1, as well as F-src-1 and CBP (CREB-binding pro-
tein), have been shown to enhance theN/C interaction (15, 50),
indicating that this conformation of the AR is not only an
important first step in the metabolism of the AR but may itself
be further stabilized by coactivator binding, as suggested previ-
ously (51). Moreover, the finding that the melanoma antigen
gene protein, MAGE-11, plays a role in modulating both AR
metabolism and coregulator binding in response to the N/C
interaction (49, 52, 53) suggests another candidate protein
interaction through which the N/C interaction might play a
role in disease. Additional studies are needed to understand
whether a role exists forMAGE-11 and/or other coregulators in
the pathogenesis of SBMA.
The AR plays an important role in both neural and muscle
functions; thus, maintaining AR function represents an impor-
tant component of an ideal therapeutic strategy for SBMA. The
recent identification of alternative AR ligands that promote AR
transcriptional activity while preventing the N/C interaction,
combined with our results revealing the essential role of the
N/C interaction in the alteredmetabolism of the expanded AR,
suggested to us that these ligands could represent a powerful
new avenue to explore for therapeutic tools to treat SBMA.Our
finding that at least two of these ligands inhibit AR aggregation
and toxicity in PC12 cells and primary mouse SBMA motor
neurons supports this idea and suggests an exciting new avenue
for therapeutic development. Further studies are currently
under way to identify optimal N/C-inhibiting ligands for the
treatment of SBMA.
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